Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064285 · ClinicalTrials.gov registry record · Phase 1
Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer
A Phase 1 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00064285 is a Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 22 participants.
The verdict
NCT00064285, a Phase 1 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy such as flavopiridol use different ways to stop cancer cells from dividing so they stop growing or die. Combining imatinib mesylate with flavopiridol may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of flavopiridol and imatinib mesylate in treating patients with hematologic cancer.
Interventions
- DRUG imatinib mesylate
- DRUG alvocidib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2003-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00064285
The ClinicalTrials.gov registry entry for NCT00064285 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which imatinib mesylate is the first listed.
NCT00064285 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00064285 about?
NCT00064285 is a clinical study titled "Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer". RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy such as flavopiridol use different ways to stop cancer cells from dividing so they stop growing or die. Combining imatinib mesylate with flavopiridol ...
What is the current status of trial NCT00064285?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2003-06.
What interventions are being tested in trial NCT00064285?
The interventions under investigation include: imatinib mesylate (DRUG), alvocidib (DRUG).
Who is sponsoring clinical trial NCT00064285?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.